Ranbaxy (India) holds 0 active US FDA Type II Drug Master Files and 1 inactive and has DMF or CEP filings on record for 1 active ingredient. 14 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Ranbaxy: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/ranbaxy

Overview

Ranbaxy is a pharmaceutical company headquartered in Gurgaon, India.

Active ingredients with DMF or CEP filings

Substances for which Ranbaxy holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Ranbaxy holds 0 active (1 total) FDA Type II Drug Master File. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • ACYCLOVIR DRUG SUBSTANCEInactive1996-10-08

FDA compliance signals

14 FDA enforcement records linked to this company.

  • recall — Class II2015-08-12

    Incorrect/Undeclared Excipients: Product contains undeclared FD&C Yellow No. 5 in the capsule shell.

  • recall — Class II2014-03-05

    Presence of Foreign Tablets: A product complaint was received by a pharmacist who discovered an Atorvastatin 20 mg tablet inside a sealed bottle of 90-count Atorvastatin 10 mg.

  • recall — Class III2013-02-20

    Crystallization: Recall is due to a non-characteristic gritty/sandy texture to the product which is likely due to some crystallization of the product.

  • recall — Class III2013-02-20

    Crystallization: Recall is due to a non-characteristic gritty/sandy texture to the product which is likely due to some crystallization of the product.

  • recall — Class II2012-12-05

    Presence of Particulate Matter: Certain batches of Atorvastatin tablets 10 mg, 20 mg and 40 mg may contain small glass particulates.

  • recall — Class II2012-12-05

    Presence of Particulate Matter: Certain batches of Atorvastatin tablets 10 mg, 20 mg and 40 mg may contain small glass particulates.

  • recall — Class II2012-12-05

    Presence of Particulate Matter: Certain batches of Atorvastatin tablets 10 mg, 20 mg and 40 mg may contain small glass particulates.

  • recall — Class II2012-11-28

    Adulterated Presence of Foreign Tablets: A product complaint was received by a pharmacist who discovered an Atorvastatin 20 mg tablet inside a sealed bottle of 90-count Atorvastatin 10 mg.

  • recall — Class III2012-07-11

    Subpotent (Single Ingredient Drug): out-of-specification result for coal tar content assay.

  • 4832011-06-22

    Late submission of 15-day report

  • 4832011-06-22

    Incomplete periodic safety report

  • 4832011-06-22

    Submission of report follow-up

  • 4832011-06-22

    Failure to develop written procedures

  • 4832009-09-29

    Investigations of discrepancies, failures

For suppliers

Is this Ranbaxy?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.